Celgene reports positive data from multiple sclerosis drug trial

Celgene has announced that its new multiple sclerosis drug ozanimod has demonstrated its effectiveness in a clinical trial.

Data has been reported from the phase III SUNBEAM trial, which evaluated the efficacy and safety of the investigational oral, selective S1P 1 and 5 receptor modulator in patients with relapsing multiple sclerosis.

It was shown that Celgene's therapy met its primary endpoint by reducing annualised relapse rates compared to an established weekly treatment option, while also helping to address the lesions associated with the condition.

A total of 1,346 patients in 20 countries were enrolled in the SUNBEAM trial, data from which will be used to support planned regulatory submissions for ozanimod before the end of the year.

Scott Smith, president of Celgene's inflammation and immunology business, said: "People living with multiple sclerosis need additional therapies and we are pleased that oral ozanimod showed meaningful improvements across primary and measured secondary endpoints in this study."

The company is also expecting confirmatory results from the phase III RADIANCE trial in the second quarter of the year.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.